stockrow
Saturday 7 November 2026
Export MLTX’s income statement to Excel — free account
MoonLake Immunotherapeutics
MLTX Healthcare Biotechnology
- EPS
- +3.45%
- Free cash flow
- −1.89%
- Total debt
- +35.6%
Quarter to June 2026, against a year earlier
11.49
0.69
+6.39%
Follow MLTX
Alert me
MoonLake Immunotherapeutics (MLTX) P/E ratio
MoonLake Immunotherapeutics has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 155× (December 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 155×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ODTX Odyssey Therapeutics, Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics | n/m |
| SVRA Savara Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| IMTX Immatics N.V. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR compare | 34.2× |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)